Barclays analyst Balaji Prasad raised the firm’s price target on Ligand (LGND) to $125 from $110 and keeps an Overweight rating on the shares as part of a Q3 preview for the specialty pharmaceuticals.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND: